BRISTOL-MYERS SQUIBB COMPANY Equity Securities, FV-NI, Unrealized Gain (Loss)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $50.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $50.00M, a 1150.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $35.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $125.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $166.00M, a 403.03% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $291.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$41.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$117.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$762.00M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $50.00M 10-Q · filed 2026-07-30 | $85.00M 10-Q · filed 2026-07-30 | $210.00M derived: sum of 3 quarters · filed 2026-07-30 | $376.00M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $35.00M 10-Q · filed 2026-04-30 | $160.00M derived: sum of 2 quarters · filed 2026-04-30 | $326.00M derived: sum of 3 quarters · filed 2026-04-30 | $330.00M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-12-31 | $125.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $291.00M derived: sum of 2 quarters · filed 2026-02-11 | $295.00M derived: sum of 3 quarters · filed 2026-07-30 | $291.00M 10-K · filed 2026-02-11 | |||
| 2025-09-30 | $166.00M 10-Q · filed 2025-10-30 | $170.00M derived: sum of 2 quarters · filed 2026-07-30 | $166.00M 10-Q · filed 2025-10-30 | -$31.00M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-06-30 | $4.00M 10-Q · filed 2026-07-30 | -$1.00M 10-Q · filed 2026-07-30 | -$197.00M derived: sum of 3 quarters · filed 2026-07-30 | -$164.00M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-03-31 | -$5.00M 10-Q · filed 2026-04-30 | -$201.00M derived: sum of 2 quarters · filed 2026-04-30 | -$168.00M derived: sum of 3 quarters · filed 2026-04-30 | -$132.00M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2024-12-31 | -$196.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$163.00M derived: sum of 2 quarters · filed 2026-02-11 | -$127.00M derived: sum of 3 quarters · filed 2026-02-11 | -$41.00M 10-K · filed 2026-02-11 | |||
| 2024-09-30 | $33.00M 10-Q · filed 2025-10-30 | $69.00M derived: sum of 2 quarters · filed 2025-10-30 | $155.00M 10-Q · filed 2025-10-30 | $241.00M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2024-06-30 | $36.00M 10-Q · filed 2025-07-31 | $122.00M 10-Q · filed 2025-07-31 | $208.00M derived: sum of 3 quarters · filed 2026-02-11 | $193.00M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2024-03-31 | $86.00M 10-Q · filed 2025-04-24 | $172.00M derived: sum of 2 quarters · filed 2026-02-11 | $157.00M derived: sum of 3 quarters · filed 2026-02-11 | $110.00M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2023-12-31 | $86.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $71.00M derived: sum of 2 quarters · filed 2026-02-11 | $24.00M derived: sum of 3 quarters · filed 2026-02-11 | -$117.00M 10-K · filed 2026-02-11 | |||
| 2023-09-30 | -$15.00M 10-Q · filed 2024-10-31 | -$62.00M derived: sum of 2 quarters · filed 2024-10-31 | -$203.00M 10-Q · filed 2024-10-31 | -$38.00M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-06-30 | -$47.00M 10-Q · filed 2024-07-26 | -$188.00M 10-Q · filed 2024-07-26 | -$23.00M derived: sum of 3 quarters · filed 2025-02-12 | -$98.00M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-03-31 | -$141.00M 10-Q · filed 2024-04-25 | $24.00M derived: sum of 2 quarters · filed 2025-02-12 | -$51.00M derived: sum of 3 quarters · filed 2025-02-12 | -$305.00M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | $165.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $90.00M derived: sum of 2 quarters · filed 2025-02-12 | -$164.00M derived: sum of 3 quarters · filed 2025-02-12 | -$762.00M 10-K · filed 2025-02-12 | |||
| 2022-09-30 | -$75.00M 10-Q · filed 2023-10-26 | -$329.00M derived: sum of 2 quarters · filed 2023-10-26 | -$927.00M 10-Q · filed 2023-10-26 | -$1.42B derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-06-30 | -$254.00M 10-Q · filed 2023-07-27 | -$852.00M 10-Q · filed 2023-07-27 | -$1.35B derived: sum of 3 quarters · filed 2024-02-13 | -$1.37B derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-03-31 | -$598.00M 10-Q · filed 2023-04-27 | -$1.09B derived: sum of 2 quarters · filed 2024-02-13 | -$1.12B derived: sum of 3 quarters · filed 2024-02-13 | -$1.20B derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2021-12-31 | -$496.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$518.00M derived: sum of 2 quarters · filed 2024-02-13 | -$599.00M derived: sum of 3 quarters · filed 2024-02-13 | -$403.00M 10-K · filed 2024-02-13 | |||
| 2021-09-30 | -$22.00M 10-Q · filed 2022-10-26 | -$103.00M derived: sum of 2 quarters · filed 2022-10-26 | $93.00M 10-Q · filed 2022-10-26 | $480.00M derived: sum of 4 quarters · filed 2023-02-14 | |||
| 2021-06-30 | -$81.00M 10-Q · filed 2022-07-27 | $11.00M 10-Q · filed 2021-07-28 | $115.00M 10-Q · filed 2022-07-27 | $448.00M 10-Q · filed 2021-07-28 | $502.00M derived: sum of 3 quarters · filed 2023-02-14 | $672.00M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-03-31 | $196.00M 10-Q · filed 2022-04-29 | $437.00M 10-Q · filed 2021-04-29 | $583.00M derived: sum of 2 quarters · filed 2023-02-14 | $753.00M derived: sum of 3 quarters · filed 2023-02-14 | $1.53B derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2020-12-31 | $387.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $557.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.33B derived: sum of 3 quarters · filed 2023-02-14 | $964.00M 10-K · filed 2023-02-14 | $1.17B 10-K · filed 2021-02-10 | ||
| 2020-09-30 | $170.00M 10-Q · filed 2021-10-27 | $948.00M derived: sum of 2 quarters · filed 2021-10-27 | $577.00M 10-Q · filed 2021-10-27 | $985.00M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-06-30 | $778.00M 10-Q · filed 2021-07-28 | $635.00M 10-Q · filed 2020-08-06 | $550.00M 10-Q · filed 2021-07-28 | $407.00M 10-Q · filed 2020-08-06 | $815.00M derived: sum of 3 quarters · filed 2022-02-09 | $580.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-03-31 | -$228.00M 10-Q · filed 2021-04-29 | $37.00M derived: sum of 2 quarters · filed 2022-02-09 | -$198.00M derived: sum of 3 quarters · filed 2022-02-09 | -$139.00M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | $265.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $30.00M derived: sum of 2 quarters · filed 2022-02-09 | $89.00M derived: sum of 3 quarters · filed 2022-02-09 | $170.00M 10-K · filed 2022-02-09 | $156.00M 10-K · filed 2020-02-24 | ||
| 2019-09-30 | -$235.00M 10-Q · filed 2020-11-05 | -$176.00M derived: sum of 2 quarters · filed 2020-11-05 | -$95.00M 10-Q · filed 2020-11-05 | -$363.00M derived: sum of 4 quarters · filed 2021-02-10 | |||
| 2019-06-30 | $59.00M 10-Q · filed 2020-08-06 | $140.00M 10-Q · filed 2020-08-06 | -$128.00M derived: sum of 3 quarters · filed 2021-02-10 | -$31.00M derived: sum of 4 quarters · filed 2021-02-10 | |||
| 2019-03-31 | $81.00M 10-Q · filed 2020-05-07 | -$187.00M derived: sum of 2 quarters · filed 2021-02-10 | -$90.00M derived: sum of 3 quarters · filed 2021-02-10 | -$464.00M derived: sum of 4 quarters · filed 2021-02-10 | |||
| 2018-12-31 | -$268.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | -$171.00M derived: sum of 2 quarters · filed 2021-02-10 | -$545.00M derived: sum of 3 quarters · filed 2021-02-10 | -$530.00M 10-K · filed 2021-02-10 | -$537.00M 10-K · filed 2019-02-25 | ||
| 2018-09-30 | $97.00M 10-Q · filed 2019-10-31 | -$277.00M derived: sum of 2 quarters · filed 2019-10-31 | -$262.00M 10-Q · filed 2019-10-31 | ||||
| 2018-06-30 | -$374.00M 10-Q · filed 2019-07-25 | -$359.00M 10-Q · filed 2019-07-25 | |||||
| 2018-03-31 | $15.00M 10-Q · filed 2019-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |